A Phase 1, Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Oral Dose of CC-220 and to Explore the Effect of Food on the Bioavailability of CC-220 in Healthy Subjects
Latest Information Update: 03 Feb 2022
At a glance
- Drugs Iberdomide (Primary)
- Indications Immunological disorders; Multiple myeloma; Systemic lupus erythematosus
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Celgene Corporation
- 26 Jun 2018 Results (n=56) published in the Annals of the Rheumatic Diseases
- 02 Nov 2013 New trial record